MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
76.87
+3.07 (+4.16%)
At close: 4:02PM EDT

76.04 -0.83 (-1.08%)
After hours: 6:43PM EDT

Stock chart is not supported by your current browser
Previous Close73.80
Open75.98
Bid76.04 x 800
Ask77.50 x 1300
Day's Range74.03 - 77.12
52 Week Range65.25 - 92.64
Volume11,590,226
Avg. Volume13,664,384
Market Cap194.963B
Beta (5Y Monthly)0.69
PE Ratio (TTM)20.18
EPS (TTM)3.81
Earnings DateApr 27, 2020
Forward Dividend & Yield2.44 (3.31%)
Ex-Dividend DateMar 12, 2020
1y Target Est96.56
  • Business Wire

    Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

    Merck Announces KEYTRUDA Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced MSI-H or dMMR Colorectal Cancer

  • Business Wire

    Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28

    Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28

  • Merck, Pfizer, Eli Lilly launch worker volunteer programs to aid in coronavirus fight
    American City Business Journals

    Merck, Pfizer, Eli Lilly launch worker volunteer programs to aid in coronavirus fight

    Major drugmakers Merck & Co. Inc.,, Pfizer Inc. and Eli Lilly and Co. are joining together to establish volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay.

  • Business Wire

    Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

    Medical Professionals Across Merck, Pfizer and Eli Lilly Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

  • Cancer startup raises $125M for Keytruda combo drug trial
    American City Business Journals

    Cancer startup raises $125M for Keytruda combo drug trial

    RA Capital and Boxer Capital continued a busy financing week, investing undisclosed amounts in a local startup working with cancer giant Merck & Co.

  • GuruFocus.com

    US Indexes Close Higher Monday

    S&P; 500 up 3.35% Continue reading...

  • GuruFocus.com

    FDA Decisions on 5 Drugs Expected in 2nd Quarter

    Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...

  • MarketWatch

    Johnson & Johnson, Merck share gains lead Dow's nearly 725-point surge

    DOW UPDATE The Dow Jones Industrial Average is soaring Monday afternoon with shares of Johnson & Johnson and Merck delivering strong returns for the index. Shares of Johnson & Johnson (JNJ) and Merck (MRK) have contributed to the blue-chip gauge's intraday rally, as the Dow (DJIA) is trading 720 points, or 3.

  • MarketWatch

    Johnson & Johnson, Merck share gains contribute to Dow's nearly 575-point surge

    DOW UPDATE Shares of Johnson & Johnson and Merck are trading higher Monday afternoon, sending the Dow Jones Industrial Average soaring. The Dow (DJIA) was most recently trading 571 points (2.6%) higher, as shares of Johnson & Johnson (JNJ) and Merck (MRK) are contributing to the index's intraday rally.

  • MarketWatch

    Dow soars 438 points on gains for Microsoft, Johnson & Johnson shares

    DOW UPDATE Shares of Microsoft and Johnson & Johnson are posting positive growth Monday afternoon, sending the Dow Jones Industrial Average soaring. The Dow (DJIA) is trading 438 points higher (2.0%), as shares of Microsoft (MSFT) and Johnson & Johnson (JNJ) have contributed to the index's intraday rally.

  • MarketWatch

    Johnson & Johnson, Microsoft share gains lead Dow's 525-point surge

    DOW UPDATE Led by strong returns for shares of Johnson & Johnson and Microsoft, the Dow Jones Industrial Average is soaring Monday afternoon. The Dow (DJIA) is trading 529 points higher (2.4%), as shares of Johnson & Johnson (JNJ) and Microsoft (MSFT) are contributing to the blue-chip gauge's intraday rally.

  • MarketWatch

    Johnson & Johnson, Intel share gains lead Dow's 425-point rally

    DOW UPDATE The Dow Jones Industrial Average is rallying Monday morning with shares of Johnson & Johnson and Intel delivering strong returns for the blue-chip average. Shares of Johnson & Johnson (JNJ) and Intel (INTC) are contributing about one third of the index's intraday rally, as the Dow (DJIA) is trading 427 points, or 2.

  • MarketWatch

    Dow's 325-point rally highlighted by gains in shares of Johnson & Johnson, Intel

    DOW UPDATE Led by positive growth for shares of Johnson & Johnson and Intel, the Dow Jones Industrial Average is rallying Monday morning. The Dow (DJIA) is trading 328 points, or 1.5%, higher, as shares of Johnson & Johnson (JNJ) and Intel (INTC) are contributing about a third of the blue-chip gauge's intraday rally.

  • Reuters

    Merck and Bayer's heart drug vericiguat meets primary efficacy endpoint in Phase 3 study

    Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary efficacy endpoint in the VICTORIA trial. The VICTORIA trial is a Phase 3 study evaluating the efficacy and safety of the drug vericiguat, which is being jointly developed with Bayer AG, the company said. Compared with a placebo, the drug reduced the risk of heart failure hospitalization or cardiovascular death in heart failure patients with reduced ejection fraction (HFrEF) when given in combination with available therapies, Merck said.

  • Business Wire

    Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies

    Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death

  • $110M injection powers up Peninsula vaccine maker — but not for COVID-19
    American City Business Journals

    $110M injection powers up Peninsula vaccine maker — but not for COVID-19

    The vaccine, expected to produce data from a clinical trial in 2022, is designed to essentially carry 24 vaccines in one against pneumonia.

  • J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months
    Yahoo Finance

    J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months

    Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.

  • Business Wire

    Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response

    Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response

  • UPS Seeks To Accelerate Growth Of Drone-Delivery
    Benzinga

    UPS Seeks To Accelerate Growth Of Drone-Delivery

    United Parcel Service (NYSE: UPS) has announced a collaboration with Wingcopter, a German-based electric vertical take-off and landing (VTOL) aircraft startup, to scale up its drone delivery operations in the U.S. and across the world. Wingcopter will be working with UPS Flight Forward (UPSFF), the drone delivery subsidiary of UPS, to create this next generation of package delivery drones. "Drone delivery is not a one-size-fits-all operation. Our collaboration with Wingcopter helps pave the way for us to start drone delivery service in new use-cases. UPS Flight Forward is building a network of technology partners to broaden our unique capability to serve customers and extend our leadership in drone delivery," said Bala Ganesh, vice president of the UPS Advanced Technology Group. The drone delivery segment has gained momentum in recent years, thanks to the ever-growing importance of expedited delivery, especially within the ecommerce market. With delivery speed being considered an important marker of end consumers' satisfaction, logistics companies see the relevance in investing across two distinct unmanned VTOL drone segments – long-range heavy-haul and short-range light-haul aircraft. While heavy-haul drones are typically used to deliver across remote and impoverished regions, light-haul drones are helpful across the last-mile delivery segment, particularly for hastening delivery in urban spaces with frequent traffic deadlock. For UPS, the partnership with Wingcopter will be within the heavy-haul VTOL aircraft segment, following Wingcopter's track record in "delivering a variety of goods over long distances in multiple international settings."The Wingcopter collaboration is UPSFF's first venture with a drone manufacturer. In a statement, UPS has stated that the companies will jointly work to gain regulatory certification for commercial flight of unmanned drones in the U.S., as well as building a diverse fleet of drones with varying capabilities to meet different customer needs. "We are proud to partner with UPS, a global giant in delivery and logistics. Together we aspire to extend the speed and reach of package delivery," said Tom Plümmer, Wingcopter chief executive officer and co-founder. "Our vision has always been to leverage technology to improve the lives of people around the world, and the strategic relationship with UPS will further accelerate our growth and global expansion, strengthening our role as an industry leader in drone technology."Wingcopter comes into this partnership fresh from the successful completion of its first drone delivery trial this February with healthcare giant Merck, delivering a shipment from a Merck & Co., Inc. (NYSE: MRK) lab in Gernsheim, Germany, to the Merck headquarters in Darmstadt, Germany. The test was a beyond the visual line of sight (BVLOS) project, which meant that the drone flew over inhabited regions that included buildings, electric power lines, traffic and people. The drone startup has considerable experience in delivering shipments for BVLOS projects across several domains, including commercial factory-to-factory deliveries, humanitarian programs and medical emergencies. Wingcopter's VTOL aircraft is unique in the market, as its patented tilt-rotor mechanism enables a seamless transition between two drone modes – multicopter for hovering and fixed-wing for low-noise forward flight. These modes help the drone to stabilize itself even when faced with harsh weather conditions, including wind speeds of up to 45 mph. The aircraft can reach speeds up to 150 mph with a range of approximately 75 miles. See more from Benzinga * Courier Giants Help U.S. Operate Pop-Up Virus Test Centers * Vehicle Electrification Is Not Just About Reducing Emissions * Today's Pickup: Amazon Insourcing Hurting DHL Globally(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
    Zacks

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

  • Business Wire

    Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City

    Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City

  • Barrons.com

    Market Experts Say the Coronavirus Selloff Is ‘Worse Than Anything We’ve Seen Since 1929.’ Here’s How Bad It Could Get.

    Technical analysis offers unique insights into market trends, especially in times of chaos. Why three practitioners see support for the S&P 500 around 2300. What the charts say about oil, emerging markets, health care, Walmart.

  • Business Wire

    Merck Recommends Rejection of TRC Capital’s "Mini-Tender" Offer

    Merck Recommends Rejection of TRC Capital’s "Mini-Tender" Offer

  • Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
    Zacks

    Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

    Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

  • Maryland biotech CEO: Virus outbreak won't stop opening of Boston R&D hub
    American City Business Journals

    Maryland biotech CEO: Virus outbreak won't stop opening of Boston R&D hub

    While biopharma companies and academic laboratories close up shop, Sensei Biotherapeutics plans to open a research hub in SmartLab’s Seaport facility.